1. Introduction
===============

Recent progress in targeted cancer therapy has revealed the importance of intratumoral heterogeneity. The presence of multiple genotypically and/or phenotypically distinct cell subpopulations within a single tumor causes therapeutic resistance and poor prognosis of cancer \[[@B1-cancers-06-01570]\]. More recently, the complexity of cancers has been associated with the heterogeneity of the tumor microenvironment, including neoplastic cells and their surrounding stromal cells \[[@B2-cancers-06-01570]\]. In solid tumors, stromal cells contain a variety of mesenchymal cells, such as fibroblasts, myofibroblasts, pericytes, and endothelial cells, and a variety of inflammatory cells \[[@B3-cancers-06-01570]\].

Among the stromal cells, cancer-associated fibroblasts (CAFs) play pivotal roles in cancer growth, progression, metastasis, and therapeutic resistance \[[@B4-cancers-06-01570]\]. CAFs produce paracrine growth factors, proteolytic enzymes, and extracellular matrix (ECM) components and interact with neoplastic cells \[[@B5-cancers-06-01570]\]. Changes in the tumor microenvironment are due not only to different mutations within tumor cells but also to the complex interplay between diverse tumor cell types and CAFs \[[@B6-cancers-06-01570]\]. In order to tackle the therapeutic difficulties of cancers, it is first important to understand the mechanisms involved in this changing tumor microenvironment, and hence, to reveal the characteristics of CAFs.

In our previous study, we established a primary culture of breast cancer cells, designated as MCKH (mammary carcinoma from KH), which exhibited a mesenchymal morphology and showed epithelial-mesenchymal transition and cancer stem cell characteristics \[[@B7-cancers-06-01570]\]. In the present study, we conducted more extensive analysis of this primary culture and revealed evidence of a CAF phenotype. The implications of the simultaneous expression of tumorigenic and CAF phenotypes are discussed herein.

2. Results and Discussion
=========================

2.1. Gene Expression Profile of MCKH Cells
------------------------------------------

The gene expression profile of MCKH cells was analyzed. Total RNAs extracted from extirpated normal and malignant tissues, CRL8798, and MCKH primary cultured cells were analyzed with Agilent SurePrint G3 Human Gene Expression 8 × 60 K. Expression profiles were determined as fold changes compared to expression levels in normal tissue. The results are summarized in [Table 1](#cancers-06-01570-t001){ref-type="table"}.

Recent studies have revealed some molecular markers of CAFs, including α-smooth muscle actin \[[@B8-cancers-06-01570]\], collagens \[[@B9-cancers-06-01570]\], and metallopeptidases \[[@B10-cancers-06-01570]\]. In MCKH cells, smooth muscle actin α2 (SACTA2) and type I collagen α2 (COLA1) were up-regulated by 2.1-fold and 35.3-fold, respectively, and matrix metallopeptidase 1 (MMP1) was considerably up-regulated, by more than 2900-fold. Other previous studies also suggested the up-regulation of growth factors such as fibroblast growth factor (FGF), transforming growth factor-β (TGF-β), and vascular endothelial growth factor (VEGF) \[[@B2-cancers-06-01570],[@B11-cancers-06-01570]\] as CAF markers. In this study, the expression of basic FGF (FGF2), TGF-β1, and VEGFA was markedly up-regulated. In addition, *v*-akt murine thymoma viral oncogene homolog 1 (AKT1), angiopoietin 1 (AGPT1), and acidic FGF (FGF1) expression was also up-regulated. These alterations in reliable CAF marker genes suggested that MCKH cells are indeed CAFs.
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###### 

Expression profiles of CAF-related genes in MCKH cells.

  Gene name               Gene                                            malignant tissue \*   CRL8798 \*        MCKH \*
  ----------------------- ----------------------------------------------- --------------------- ----------------- -------------------
  transcription factors                                                                                           
  HIF1A                   hypoxia inducible factor 1, α subunit           1.28 ± 0.16           3.93 ± 0.16       9.40 ± 1.30
  NFKB2                   NF-κB2                                          1.04 ± 0.12           4.25 ± 0.50       2.07 ± 0.30
  BNIP3                   BCL2/adenovirus E1B interacting protein 3       0.77 ± 0.02           11.72 ± 0.23      20.85 ± 0.72
  glycolytic enzymes                                                                                              
  GAPDH                   glyceraldehyde-3-phosphate dehydrogenase        1.08 ± 0.02           8.11 ± 0.23       16.78 ± 0.47
  LDHA                    lactate dehydrogenase A                         1.05 ± 0.05           21.22 ± 3.08      32.17 ± 5.40
  PGAM1                   phosphoglycerate mutase 1                       1.3 ± 0.50            10.84 ± 0.49      17.22 ± 2.79
  PGK1                    phosphoglycerate kinase 1                       1.35 ± 0.04           10.83 ± 0.19      15.67 ± 0.62
  ALDOA                   aldolase A, fructose-bisphosphate               1.81                  5.95              8.39
  ENO1                    enolase 1, α                                    0.58                  12.00             10.15
  PKM2                    pyruvate kinase, muscle                         1.31                  11.59             18.56
  TPI1                    triosephosphate isomerase 1                     1.06                  9.04              13.87
  transporters                                                                                                    
  SLC16A1                 monocarboxylic acid transporter 1               0.97                  14.34             12.03
  SLC16A3                 monocarboxylic acid transporter 4               5.44                  116.02            136.50
  SLC1A5                  neutral amino acid transporter                  0.50                  4.16              25.87
  others                                                                                                          
  COLA2                   collagen, type I, α2                            26.20 ± 1.70          0.0006 ± 0.0002   35.32 ± 2.13
  MMP1\*\*                matrix metallopeptidase 1                       1.05 ± 0.55           52.62 ± 19.16     2942.30 ± 1107.47
  CAV1                    caveolin 1, caveolae protein                    0.28 ± 0.02           4.17 ± 0.36       0.95 ± 0.05
  CAV2                    caveolin 2                                      0.34 ± 0.03           4.64 ± 1.40       2.31 ± 0.67
  AKT1                    v-akt murine thymoma viral oncogene homolog 1   1.33                  2.22              3.22
  ANGPT1                  angiopoietin 1 (ANGPT1)                         0.63                  0.07              6.59
  FGF1                    fibroblast growth factor 1 (acidic)             0.66 ± 0.41           0.53 ± 0.68       2.49 ± 0.97
  FGF2                    fibroblast growth factor 2 (basic)              0.22 ± 0.01           0.98 ± 0.05       9.38 ± 0.67
  TGFB1\*\*               transforming growth factor, β1                  3.59 ± 0.20           6.31 ± 0.28       10.04 ± 0.54
  VEGFA                   vascular endothelial growth factor A            0.86 ± 0.01           1.96 ± 0.33       8.88 ± 2.73
  CXCL12                  chemokine (C-X-C motif) ligand 12               0.20 ± 0.005          0.0003 ± 0.0001   0.03 ± 0.002
  CXCR4                   chemokine (C-X-C motif) receptor 4              2.87 ± 0.07           0.003 ± 0.0003    0.008 ± 0.0008
  SACTA2                  actin, α2, smooth muscle                        0.43                  0.04              2.10

\* Expression profiles were calculated as fold-changes compared to expression in normal tissue. Each value represents the average of more than two features from the gene chip. Data obtained from more than three features are presented with their SDs; \*\* These data have already been reported in our previous paper \[[@B7-cancers-06-01570]\].

The oxygen-responsive hypoxia-inducible factor 1α (HIF1A) gene is overexpressed in a variety of carcinomas and their metastases \[[@B12-cancers-06-01570]\]. HIF1A and its downstream target genes, including nuclear factor of κ light polypeptide gene enhancer in B-cells (NF-κB) and BCL2/adenovirus E1B interacting protein 3 (BNIP3), are also activated in CAFs \[[@B13-cancers-06-01570]\]. Consequently, CAFs up-regulate the expression of glycolytic enzymes and glucose transporters \[[@B14-cancers-06-01570]\]. HIF1A expression in MCKH cells was 9.4-fold higher than that in normal tissue. This HIF1A up-regulation was even higher than that observed in tumor tissue and a normal mammary gland breast epithelial cell line. Moreover, NF-κB and BNIP3 were also up-regulated in MCKH cells. Thus, MCKH cells show up-regulated expression of glycolytic enzymes and glucose transporters, several of which were up-regulated by more than 10-times compared to normal tissue. Some were drastically activated; for example, expression levels of lactate dehydrogenase A (LDHA) and monocarboxylic acid transporter 4 (SLC16A3) were 32-fold and 136-fold higher than those in normal tissue, respectively. These results provided compelling evidence that MCKH cells show the "reverse Warburg effect \[[@B14-cancers-06-01570]\]".

Another established CAF marker is down-regulation of caveolin-1 (CAV1) \[[@B14-cancers-06-01570]\]. However, in this study, CAV1 expression was not changed. In addition, some previous reports suggested the up-regulation of stromal cell-derived factor 1 (SDF1)/chemokine (C-X-C motif) ligand 12 (CXCL12) signaling and chemokine (C-X-C motif) receptor 4 (CXCR4) as a reliable markers for CAFs \[[@B10-cancers-06-01570],[@B11-cancers-06-01570]\]. However, in the present study, both CXCL12 and CXCR4 were strikingly down-regulated; thus, these results did not support MCKH cells as CAFs.

In order to find abnormalities in cell cycle control, we evaluated the expression of cell cycle-controlling genes ([Table 2](#cancers-06-01570-t002){ref-type="table"}). Many cyclin and cyclin-dependent kinase genes were up-regulated, suggesting that MCKH cells were actively proliferating. On the other hand, cyclin-dependent kinase inhibitor (CKI) genes were also up-regulated. Overexpression of CKI genes, for example, CDKN1A (p21 or Cip1), results in cell cycle exit and activation of the differentiation program \[[@B15-cancers-06-01570]\]. In the present study, many CKI genes, including CDKN1A, were also up-regulated, suggesting that MCKH cells were differentiated. Moreover, expression levels of TP53 (p53) and retinoblastoma 1 (RB1) were not significantly changed in this study. On the basis of these results, it was difficult to determine the state of cell cycle control, proliferation or differentiation, of MCKH cells.

2.2. CAF Properties of MCKH Cells
---------------------------------

The most convincing evidence for the CAF property is enhancement of tumor growth. The human breast adenocarcinoma cell line MCF-7 and the normal mammary gland breast epithelial cell line CRL-8797 were cultured in MCKH- and human dermal fibroblast (HDF)-conditioned media (CM). As shown in [Figure 1](#cancers-06-01570-f001){ref-type="fig"}a, MCKH-CM significantly (*p* = 0.022) enhanced the proliferation of MCF-7 cells, but not of CRL-8797 cells. This result supported the CAF property of MCKH cells. However, similar enhancement of tumor growth was also observed with HDF-CM.

The enhancement of tumor growth by CAFs is suggested to be mediated by FGF signaling \[[@B2-cancers-06-01570],[@B16-cancers-06-01570]\]. In order to determine the relationship between MCKH-CM activity and FGF signaling, MCF-7 cells were treated with FGF and/or tyrosine-kinase inhibitors (SU5402, U-0126). Treatment of SU5402 and U-0126 in the control medium decreased the proliferation of MCF-7 cells, suggesting that these inhibitors inhibited some growth signals activated by the serum contained in the control medium. The MCKH-CM was significantly enhanced the proliferations of MCF-7 even with inhibitors, SU5402 and U0126 (*p* = 0.0003 and *p* = 0.04, respectively). Although the enhancement of proliferation of MCF-7 by adding the FGF to the normal medium was not significant in this experiment (*p* = 0.136), the effects of MCKH-CM were very similar to those of FGF ([Figure 1](#cancers-06-01570-f001){ref-type="fig"}b). It seems likely that, at least, part of MCKH-CM activity is dependent on FGF signaling.
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###### 

Expression profiles of cell-cycle-related genes in MCKH cells.

  Gene name                            Gene                 malignant tissue \*   CRL8798 \*     MCKH \*
  ------------------------------------ -------------------- --------------------- -------------- ---------------
  telomerase reverse transcriptase                                                               
  TERT                                 TERT                 1.05 ± 0.22           1.13 ± 0.25    0.82 ± 0.33
  cyclins                                                                                        
  CCNA2                                cyclin A2            1.97 ± 0.83           10.27 ± 4.05   7.92 ± 3.06
  CCNB1                                cyclin B1            0.86 ± 0.15           6.83 ± 1.37    5.72 ± 1.43
  CCND1                                cyclin D1            3.23 ± 0.11           5.79 ± 0.30    7.46 ± 0.54
  CCNE1                                cyclin E1            1.70                  10.10          4.67
  cyclin-dependent kinases                                                                       
  CDK1                                 CDK1                 1.23 ± 0.30           20.13 ± 3.86   5.36 ± 1.18
  CDK3                                 CDK3                 1.50                  1.74           2.88
  CDK5                                 CDK5                 2.06                  5.98           6.08
  CDK7                                 CDK7                 1.07                  3.34           2.72
  cyclin-dependent kinase inhibitors                                                             
  CDKN1A \*\*                          p21, Cip1            3.46                  7.81           19.86
  CDKN2A                               p16, inhibits CDK4   5.36 ± 1.79           5.10 ± 1.80    23.37 ± 10.36
  CDKN2B                               p15, inhibits CDK4   4.69                  7.66           34.42
  CDKN3                                CDKN3                2.90 ± 0.75           9.10 ± 1.87    14.23 ± 7.23
  others                                                                                         
  TP53 \*\*                            p53                  0.85 ± 0.24           2.32 ± 0.71    1.54 ± 0.52
  MDM2                                 MDM2                 2.44 ± 0.67           4.21 ± 0.74    2.61 ± 0.57
  RB1 \*\*                             retinoblastoma 1     1.15 ± 0.06           1.00 ± 0.04    0.84 ± 0.05

\* Expression profiles were calculated as fold-changes compared to expression in normal tissue. Each value represents the average of more than two features from the gene chip. Data obtained from more than three features are presented with their SDs; \*\* These data have already been reported in our previous paper \[[@B7-cancers-06-01570]\].

2.3. What Are MCKH Cells?
-------------------------

The results of this study indicated that MCKH cells show both tumor-like and stroma-like properties simultaneously. One possibility to explain this result is that MCKH primary culture represents a heterogeneous cellular population. Although, MCKH cells showed homogeneous fibroblastic morphology, and did not contain columnar-shaped epithelial-like cells, further works, such as establishment, cloning, and characterization of hTERT (human telomerase reverse transcriptase)-immortalized MCKH cell line, were needed to clarify the homogeneity. Even if the MCKH was a heterogeneous population, MCKH represents a particularly unique phenotype, which bears both tumorigenic and CAF-like properties simultaneously. This primary culture, MCKH, offers a unique experimental system for studying the biology of CAFs.

![The effects of MCKH- and HDF-conditioned media (CM). (**a**) MCF-7, a human breast adenocarcinoma cell line, and CRL-8797, a normal mammary gland breast epithelial cell line, were cultured in freshly prepared MCF medium (control), MCKH-CM, and HDF-CM. Cell proliferation was assessed by using a 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) method and evaluated relative to proliferation in the control medium. Some *p*-values of the *t*-tests are represented; (**b**) The effects of tyrosine-kinase inhibitors on the activity of MCKH-CM to MCF-7. MCF-7 was cultured in the control medium, FGF-fortified medium, and MCKH-CM, with (SU5402, U-126) or without (−) inhibitors. Cell proliferation was assessed using an MTT method and evaluated relative to proliferation in the control medium without inhibitors.](cancers-06-01570-g001){#cancers-06-01570-f001}

3. Experimental
===============

3.1. Cells and Cell Culture
---------------------------

The chemically transformed normal mammary gland breast epithelial cell line CRL-8798 was obtained from the American Type Culture Collection (Manassas, VA, USA), and the HDF and human breast adenocarcinoma cell line (MCF-7) were purchased from Summit Pharmaceuticals (Tokyo, Japan). The primary culture of breast cancer cells (MCKH) was established previously \[[@B7-cancers-06-01570]\]. MCKH cells were cultured in MCF medium \[Earle's Eagle minimum essential medium; 1 mM sodium pyruvate, 10 μg/mL bovine insulin, 1× non-essential amino acids (Sigma, St. Louis, MO, USA), 10% fetal bovine serum (EuroClone, Milano, Italy)\].

3.2. Gene Expression Profiles
-----------------------------

Total RNAs of extirpated tissues and cultured cells were extracted with RNeasy (Qiagen, Tokyo, Japan) according to the manufacturer's instructions. The gene expression profiles were analyzed with Hokkaido System Science (Sapporo, Japan) using the SurePrint G3 Human GE Microarray Kit 8 × 60 k (Agilent, Santa Clara, CA, USA). These data were compared to those obtained from normal tissues adjacent to the tumor, which were extirpated from the same patient. The patient provided written informed consent, and this study was approved by the Human Ethics Committee of Konan University (11-02).

3.3. CAF Assays
---------------

MCF-7 and CRL-8798 cells were cultured with MCKH- or HDF-CM. CM was obtained from the 24-h confluent cultures of MCKH or HDF cells with serum-starved (3%) MCF medium, and was used freshly. MCF-7 and CRL-8798 cells were cultured on 24-well plates for 48 h with CM or serum-starved (3%) MCF medium. During this culture period, culture media were replenished once. The cell proliferation rate was measured using the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) method. The difference between the peak absorbance at 570 nm and the minimal absorbance at 630 nm was calculated.

3.4. Inhibition Assays
----------------------

In order to determine whether recombinant human basic FGF (Wako, Osaka, Japan; 067-04031) could mimic the effect of CM, FGF was added to the culture medium at a final concentration of 10 ng/mL. SU5402 (3-\[4-methyl-2-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1*H*-pyrrol-3-yl\]-propionic acid; Sigma; SML0443) is a fibroblast growth factor receptor (FGFR)-specific tyrosine kinase inhibitor, and is potent in inhibiting VEGFR and PDGFR \[[@B17-cancers-06-01570]\]. U0126 (1,4-diamino-2,3-dicyano-1,4-bis\[2-aminophenylthio\]butadiene; Sigma; U120) is a highly selective inhibitor of MEK1 and MEK2. MEK1/2 is activated by a wide variety of growth factors, including FGF, PDGF, and EGF, and cytokines, as well as by membrane depolarization and calcium influx \[[@B18-cancers-06-01570]\]. Both SU5402 and U1206 were added at a final concentration of 10 μM.

4. Conclusions
==============

MCKH cells showed a phenotype intermediate between tumor and CAF cells. In other words, MCKH cells showed both tumor-like and stroma-like properties simultaneously. This unique property of MCKH cells might suggest an intriguing relationship between tumors and stroma. Furthermore, these cells provide clues for understanding the microenvironment of cancer, and can offer insight into the development of novel cancer therapies.
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